Moderna, Inc. (MRNA) grants RSUs and stock options to director Michael R. McDonnell

Rhea-AI Filing Summary

Moderna, Inc. director Michael R. McDonnell received equity-based compensation in the form of restricted stock units and a stock option. He was granted 5,733 RSUs vesting in full on July 8, 2027, 1,618 RSUs vesting in full on the earlier of May 6, 2027 or the next annual meeting, and an option for 7,415 shares at an exercise price of $73.80 per share that becomes fully vested and exercisable on July 8, 2027. The RSUs convert into common stock on a one-for-one basis.

Insights

Equity Compensation Analyst

Director received routine equity grants, increasing alignment without open-market buying or selling.

Director Michael R. McDonnell received three equity awards from Moderna, Inc.: 5,733 restricted stock units (RSUs), 1,618 RSUs, and a stock option for 7,415 shares at an exercise price of $73.80 per share. These are reported as grants, not market purchases or sales.

The 7,415-share option and the 5,733 RSUs vest in full on July 8, 2027. The 1,618 RSUs vest on the earlier of May 6, 2027 or Moderna's next annual stockholder meeting, subject to continued service. RSUs convert into common stock on a one-for-one basis, so the awards increase potential future ownership if service and vesting conditions are met.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider McDonnell Michael R.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,415	$0.00	--
Grant/Award	Restricted Stock Units	1,618	$0.00	--
Grant/Award	Restricted Stock Units	5,733	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 7,415 shares (Direct, null); Restricted Stock Units — 1,618 shares (Direct, null)

Footnotes (1)

1. This option will become fully vested and exercisable on July 8, 2027. Restricted stock units convert into common stock on a one-for-one basis. The shares subject to this restricted stock unit award will vest in full on July 8, 2027. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.

Key Figures

RSU grant 1: 5,733 RSUs RSU grant 2: 1,618 RSUs Stock option shares: 7,415 shares +3 more

6 metrics

RSU grant 1 5,733 RSUs Restricted stock unit award vesting in full on July 8, 2027

RSU grant 2 1,618 RSUs Restricted stock unit award vesting on earlier of May 6, 2027 or next annual meeting

Stock option shares 7,415 shares Stock option (right to buy) granted to director

Stock option exercise price $73.80 per share Exercise price for 7,415-share stock option

Option vesting date July 8, 2027 Date when option becomes fully vested and exercisable

Option expiration date July 8, 2036 Expiration date of the 7,415-share stock option

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), vest in full, exercise price

4 terms

Restricted Stock Units financial

"Restricted stock units convert into common stock on a one-for-one basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of 73.8000."

vest in full financial

"The shares subject to this restricted stock unit award will vest in full on July 8, 2027."

exercise price financial

"Stock option for 7,415 shares at an exercise price of $73.80 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 05:08 PM Accepted by SEC EDGAR 07/10/2026 - 05:08 PM Learn about SEC filing dates

FAQ

What equity awards did Moderna (MRNA) director Michael R. McDonnell receive?

Michael R. McDonnell received 5,733 restricted stock units, 1,618 restricted stock units, and a stock option for 7,415 shares at $73.80 per share, all as equity-based compensation awards.

When do Michael R. McDonnell’s new Moderna (MRNA) stock option and RSUs vest?

The 7,415-share option and 5,733 RSUs vest in full on July 8, 2027. The 1,618 RSUs vest on the earlier of May 6, 2027 or Moderna’s next annual meeting.

What is the exercise price of Michael R. McDonnell’s new Moderna (MRNA) stock option?

The newly granted stock option covers 7,415 shares of Moderna common stock with an exercise price of $73.80 per share, expiring on July 8, 2036, if not earlier exercised or forfeited.

How do Michael R. McDonnell’s Moderna (MRNA) restricted stock units convert to shares?

The filing states that restricted stock units convert into common stock on a one-for-one basis. Each vested RSU will result in the issuance of one share of Moderna common stock, subject to the award terms.

Does Michael R. McDonnell’s Moderna (MRNA) Form 4 show any open-market stock sales or purchases?

No open-market purchases or sales are reported. All transactions are coded as “A” grants or awards of restricted stock units and stock options, representing equity compensation rather than market trading.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McDonnell Michael R.

(Last) (First) (Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$73.8	07/08/2026		A		7,415		(1)	07/08/2036	Common Stock	7,415	$0	7,415	D
Restricted Stock Units	(2)	07/08/2026		A		1,618		(3)	(3)	Common Stock	1,618	$0	1,618	D
Restricted Stock Units	(2)	07/08/2026		A		5,733		(4)	(4)	Common Stock	5,733	$0	5,733	D

Explanation of Responses:

1. This option will become fully vested and exercisable on July 8, 2027.

2. Restricted stock units convert into common stock on a one-for-one basis.

3. The shares subject to this restricted stock unit award will vest in full on July 8, 2027.

4. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.

	/s/ James Dillon, as Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)